CD38 and hepatocellular carcinoma: Another signature, CD38, has also been proven to participate in immunosuppressive adenosinergic signaling, and an increased proportion of CD38+ cells within the immune microenvironment is predictive of the anti-PD-1/PD-L1 therapeutic response in HCC[38].